High-dose Oral Ambroxol for Early Treatment of Pulmonary Acute Respiratory Distress Syndrome: an Exploratory, Randomized, Controlled Pilot Trial

Conclusions: Among ventilated pulmonary ARDS patients with oxygenation index of <10, mortality was 26%. Ambroxol did not improve VFD. Study with higher and more frequently administered doses of ambroxol in larger sample is suggested after having generated relevant pharmacokinetic data among critically ill children.

Source: Journal of Tropical Pediatrics - October 1, 2015 Category: Tropical Medicine Authors: Baranwal, A. K., Murthy, A. S., Singhi, S. C. Tags: Original Papers Source Type: research